The Central Social Insurance Medical Council (Chuikyo) discussed the optimization of health insurance coverage for poultices and liposoluble vitamin preparations at a general meeting on December 11. At the day’s meeting, the Ministry of Health, Labor and Welfare (MHLW) presented…
To read the full story
Related Article
- FY2016 Drug Pricing Reform
August 18, 2015
REGULATORY
- Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
- Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
April 28, 2026
- Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
- Takaichi Says Govt to Weigh Response to MFN Drug Pricing Policy
April 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





